Updating results

567 results

Sort: Relevance | Date

Velmanase alfa for treating alpha-mannosidosis [ID800]

In development [GID-HST10010] Expected publication date: TBC

Highly specialised technologies guidance In development

Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

In development [GID-NG10141] Expected publication date: 17 November 2021

NICE guideline In development

Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer (CDF Review of TA557) [ID1584]

In development [GID-TA10529] Expected publication date: TBC

Technology appraisal guidance In development

Carfilzomib with dexamethasone and lenalidomide for treating multiple myeloma after at least 1 previous therapy [ID1493]

In development [GID-TA10510] Expected publication date: TBC

Technology appraisal guidance In development

Metreleptin for treating lipodystrophy (ID861)

In development [GID-HST10011] Expected publication date: TBC

Highly specialised technologies guidance In development

High-sensitivity troponin for the early rule out of acute myocardial infarction

In development [GID-DG10035] Expected publication date: 08 April 2020

Diagnostics guidance In development

ERC1671 for treating progressed or recurrent glioblastoma ID1623

In development [GID-TA10489] Expected publication date: TBC

Technology appraisal guidance In development

Epilepsies in children, young people and adults

In development [GID-NG10112] Expected publication date: 02 June 2021

NICE guideline In development

Fetal alcohol spectrum disorder

In development [GID-QS10139] Expected publication date: 31 July 2020

Quality standard In development

Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]

In development [GID-TA10314] Expected publication date: TBC

Technology appraisal guidance In development

Rheumatoid arthritis in over 16s (QS update)

In development [GID-QS10136] Expected publication date: 09 January 2020

Quality standard In development

Flu vaccination: increasing uptake

In development [GID-QS10071] Expected publication date: 09 January 2020

Quality standard In development

Non-bisphosphonates for treating osteoporosis [ID901]

In development [GID-TA10072] Expected publication date: TBC

Technology appraisal guidance In development

Isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID1477]

In development [GID-TA10448] Expected publication date: 05 August 2020

Technology appraisal guidance In development

Nivolumab in combination for untreated advanced gastric cancer [ID1465]

In development [GID-TA10352] Expected publication date: 14 July 2021

Technology appraisal guidance In development

Third molars (impacted) - prophylactic removal [ID898]

In development [GID-TAG525] Expected publication date: TBC

Technology appraisal guidance In development

Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer ID1605

In development [GID-TA10488] Expected publication date: 05 August 2020

Technology appraisal guidance In development

Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]

In development [GID-TA10498] Expected publication date: TBC

Technology appraisal guidance In development

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

In development [GID-TA10481] Expected publication date: TBC

Technology appraisal guidance In development

Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]

In development [GID-TA10491] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

In development [GID-TA10492] Expected publication date: TBC

Technology appraisal guidance In development

Erenumab for preventing migraine [ID1188]

In development [GID-TA10302] Expected publication date: 31 October 2019

Technology appraisal guidance In development

Self-harm in over 8s: short- and long-term management and prevention of recurrence

In development [GID-NG10148] Expected publication date: 26 January 2022

NICE guideline In development

Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]

In development [GID-TA10299] Expected publication date: 22 July 2020

Technology appraisal guidance In development

Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]

In development [GID-TA10513] Expected publication date: TBC

Technology appraisal guidance In development

Cannabis-based medicinal products

In development [GID-NG10124] Expected publication date: 11 November 2019

NICE guideline In development

Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab [ID1583]

In development [GID-TA10530] Expected publication date: 13 May 2020

Technology appraisal guidance In development

Faltering growth

In development [GID-QS10083] Expected publication date: 02 June 2020

Quality standard In development

Budesonide for treating active eosinophilic oesophagitis [ID1202]

In development [GID-TA10372] Expected publication date: 08 July 2020

Technology appraisal guidance In development

Pelvic floor dysfunction: prevention and non-surgical management

In development [GID-NG10123] Expected publication date: 26 August 2021

NICE guideline In development

Anakinra for treating active Stills disease [ID1463]

In development [GID-TA10392] Expected publication date: 26 June 2020

Technology appraisal guidance In development

Preterm labour and birth (update)

In development [GID-NG10078] Expected publication date: 02 August 2019

NICE guideline In development

Neratinib for treating early hormone receptor-positive HER2-positive breast cancer after adjuvant trastuzumab [ID981]

In development [GID-TA10107] Expected publication date: 20 November 2019

Technology appraisal guidance In development

Atezolizumab for untreated, locally advanced or metastatic, triple negative, PD-L1 positive breast cancer [ID1522]

In development [GID-TA10433] Expected publication date: 20 November 2019

Technology appraisal guidance In development

gammaCore for cluster headache

In development [GID-MT523] Expected publication date: 22 November 2019

Medical technologies guidance In development

Episcissors-60 for guided mediolateral episiotomy

In development [GID-MT527] Expected publication date: 30 January 2020

Medical technologies guidance In development

Postnatal care

In development [GID-NG10070] Expected publication date: 25 November 2020

NICE guideline In development

Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke

In development [GID-DG10023] Expected publication date: TBC

Diagnostics guidance In development

Diverticular disease: diagnosis and management

In development [GID-NG10064] Expected publication date: 27 November 2019

NICE guideline In development

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 [ID943]

In development [GID-HST10008] Expected publication date: 27 November 2019

Highly specialised technologies guidance In development

Idelalisib for treating follicular lymphoma refractory to 2 treatments ID1379

In development [GID-TA10290] Expected publication date: 02 October 2019

Technology appraisal guidance In development

Ustekinumab for treating moderately to severely active ulcerative colitis [ID1511]

In development [GID-TA10434] Expected publication date: 04 March 2020

Technology appraisal guidance In development

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (part review of TA301) [ID1421]

In development [GID-TA10379] Expected publication date: 20 November 2019

Technology appraisal guidance In development

Carers: provision of support for adult carers

In development [GID-NG10046] Expected publication date: 22 January 2020

NICE guideline In development

Pembrolizumab with axitinib for untreated metastatic renal cell carcinoma ID1426

In development [GID-TA10331] Expected publication date: 27 May 2020

Technology appraisal guidance In development

Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after initial platinum-based chemotherapy [ID1518]

In development [GID-TA10504] Expected publication date: TBC

Technology appraisal guidance In development

Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]

In development [GID-TA10523] Expected publication date: 16 December 2020

Technology appraisal guidance In development

Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1584]

In development [GID-TA10533] Expected publication date: 24 June 2020

Technology appraisal guidance In development